Kidney Failure Risk Equation Research Articles

Prediction of Allograft Failure in Pediatric Kidney Transplant Recipients: A Validation Study of the Four-Variable Kidney Failure Risk Equation

Prediction of Allograft Failure in Pediatric Kidney Transplant Recipients: A Validation Study of the Four-Variable Kidney Failure Risk Equation

Automated digital counselling promotes therapeutic change in mental health in patients with chronic heart failure or chronic kidney disease: ODYSSEE-vCHAT study

Abstract Background The efficacy of digital programs to improve the management of chronic heart failure (CHF) and chronic kidney disease (CKD) is not established. Building on related studies in digital health, behavioural counselling, and social support, we evaluated whether an automated digital counselling program with social network support (ODYSSEE-vCHAT) could improve mental health and health-related quality of life in patients with CHF or CKD. Purpose The primary objective was to examine whether engagement with ODYSSEE-vCHAT was associated with a minimal clinically important difference for improvement in the Mental Component Summary (MCS) of the SF-36 at end-of-study. Secondary outcomes included: ENRICHD Social Support Index (ESSI), Patient Health Questionnaire for Depression (PHQ-9) Godin-Shephard Leisure Time Physical Activity Scale (GSLTPAQ), and an index of the frequency to which patients engaged in goal-directed activities for living well (EUROIA). Methods ODYSSEE-vCHAT was a multi-centre, single group, open label study with assessments at baseline and end-of-study (approximately 11 months). Inclusion criteria were: ≥18 years of age, diagnosis of CHF (reduced ejection fraction (EF) ≤ 40%, mid-range EF, 41-49%, or preserved EF ≥ 50%); or CKD diagnosis (>10% risk for dialysis using the 4-variable, 2-year Kidney Failure Risk Equation, or on dialysis). Exclusion was based on inability to participate due to co-morbidities. The digital counselling protocol taught self-care skills to improve mental health, quality of life, and adherence to medications, exercise, diet, and smoke-free living (Figure 1). Patient engagement with ODYSSEE-vCHAT was defined as Not Engaged (0 logon minutes) vs. Engaged (> 0 logon minutes). The primary outcome was a minimal clinically important difference for MCS change: ΔMCS ≥ 3.8 or MCS ≥ 65 at baseline and study endpoint. It was assessed using multivariable binary logistic regression, controlling for exposure to COVID-19 and health literacy. Secondary outcomes were assessed using multivariable linear regression analyses with the same covariates. Results 215 patients were enrolled. There were 7 deaths and 34 withdrew. In our sample of 174 patients, mean age = 54.4 years (95% Confidence Interval, CI, 25, 81), gender identity as women, n = 68 (39%), ethno-racial group other than White, n = 83, (48%), primary diagnosis, CHF, n = 68 (39%), and CKD, n = 106 (61%). Duration of enrolment to end-of-study: median = 352 days, (95% CI, 159, 496). Engagement with ODYSSEE was associated with therapeutic change on the MCS (for both CHF and CKD patients, and CHF patients alone), GSLTPAQ, and EUROIA, but not the PHQ9 or ESSI (Figure 2). Conclusions Automated digital counselling with social network support promotes improvement in indices of mental health for patients with CHF and CKD. These findings support a follow-up randomized controlled trial.Figure 1.ODYSSEE-vCHAT Study ProtocolFiFigure 2.ODYSSEE-vCHAT Study Outcomes

Adding Biomarker Change Information to the Kidney Failure Risk Equation Improves Predictive Ability for Dialysis Dependency in eGFR <30 mL/min/1.73m2

Abstract Background Although the Kidney Failure Risk Equation (KFRE), a well-known predictive model for predicting dialysis dependency, is useful, it remains unclear whether the addition of biomarker changes to the KFRE model in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 will improve its predictive value. Methods We retrospectively identified adults with eGFR < 30 mL/min/1.73 m2 without dialysis dependency, and available health checkup data for 2 successive years using a large Japanese claims database (DeSC, Tokyo, Japan). We dichotomized the entire population into 50% training set and the other half as validation set. To assess the incremental value in the predictive ability for dialysis dependency by the addition of changes in eGFR and proteinuria, we calculated the difference in the C-statistics and net reclassification index (NRI). Results We identified 4,499 individuals and observed 422 individuals (incidence of 45.2 per 1000 person-years) who developed dialysis dependency during the observation period (9,343 person-years). Adding biomarker changes to the KFRE model improved C-statistics from 0.862 to 0.921, with an improvement of 0.060 (95% CI of 0.043–0.076, P <0.001). The corresponding NRI was 0.773 (95% CI: 0.637– 0.908), with an NRI for events of 0.544 (95% CI of 0.415–0.672) and NRI for non-events of 0.229 (95% CI of 0.186–0.272). Conclusions The KFRE model was improved by incorporating yearly changes in its components. The added information may help clinicians identify high-risk individuals and improve their care.

A-201 The Impact of Implementing the CKD-EPI 2021 Equation for Calculation of Estimated Glomerular Filtration Rate (eGFR) and the Kidney Failure Risk Equation (KFRE) on a Large Community Laboratory Population

Abstract Background Community laboratories in Ontario, Canada have reported estimated glomerular filtration rate (eGFR) using the CKD-EPI 2009 equation without race adjustment since 2020. In 2023, the Canadian Society of Nephrology recommended implementation of the CKD-EPI 2021 equation for eGFR, which does not incorporate a race-based modifier. Community laboratories will also report the 5-year Kidney Failure Risk Equation (KFRE), a risk prediction model to estimate the risk of renal failure in people with chronic kidney disease (CKD) Stages 3 to 5 (eGFR <60 mL/min/1.73m2), which is more accurate than judging by eGFR alone. This study assessed the impact of implementing the CKD-EPI 2021 equation for eGFR and the 5-year KFRE in a large community laboratory population. Methods Laboratory results for serum creatinine and urine albumin to creatinine ratio (ACR), patient sex and age were extracted from Dynacare’s laboratory information system for November 2023. The CKD-EPI 2009 without race adjustment and the CKD-EPI 2021 were calculated. Reclassification of CKD stage using the CKD-EPI 2021 equation was assessed. The 4-variable 5-year KFRE was calculated for patients in CKD Stage 3-5 (eGFR <60 mL/min/1.73m2) when all parameters including, patient age, sex, creatinine and ACR, were available. Results Data was extracted for 242,843 patients. The median age was 61 years old and 47% of the population was female. The calculated median eGFR was 83 and 87 mL/min/1.73m2 when the CKD-EPI 2009 with no race adjustment, and CKD-EPI 2021 equation, respectively, were applied. Linear regression analysis showed a correlation of 0.997 with a slope of 0.990 and y-intercept of 4.513. A total of 13.0% (n=31,679) of patients were reclassified into a less progressive CKD stage when the CKD-EPI 2021 was applied compared to the CKD-EPI 2009 without race adjustment. Notable, was the reclassification of 21.8% (n=6899) of those patients from Stage 3a to 2, i.e. patients no longer have CKD (eGFR >60 mL/min/1.73m2) based on the new calculation. 64.8% (n=20513) of patients were reclassified from Stage 2 to 1, 9.4% (n=2977) were reclassified from Stage 3b to 3a, 3.5% (n=1102) were classified from Stage 4 to 3b, and 0.6% (n=188) were reclassified from Stage 5 to 4. The 5-year KFRE was calculated when creatinine and ACR were included on the same order and the patient was classified as Stage 3 to 5 (n=12,737 patients with eGFR <60 mL/min/1.73m2). The 5-year KFRE showed increasing median risk, 1%, 4%, 27%, 95%, as CKD stage increased from 3a, 3b, 4 and 5, respectively. 1.1% (n=58) of patients in Stage 3a, 43.3% (n=1584) of patients in Stage 3b, 96.6% (n=1994) of patients in Stage 4, and 100% (n=401) of patients in Stage 5 met the KFRE threshold of ≥5% for referral to nephrology. Conclusions Implementation of the CKD-EPI 2021 resulted in reclassification to a less progressive CKD stage. Use of the KFRE as a clinical decision tool will increase patient referral to nephrology. This study provided insight into the impact of the implementation of the CKD-EPI 2021 and KFRE and highlights the underutilization of ACR in a community population.

Frequency of CKD Patient Referrals to Nephrology Clinics Using the Kidney Failure Risk Equation at Kaiser Permanente Northern California

Frequency of CKD Patient Referrals to Nephrology Clinics Using the Kidney Failure Risk Equation at Kaiser Permanente Northern California

Exploration of patients’ and healthcare professionals’ perspectives on kidney failure risk and the use of the kidney failure risk equation in MULTIPle lOng-term condItions aNd frailTy (MULTIPOINT) study: a qualitative interview and focus group study protocol

IntroductionClinical guidelines recommend the use of the kidney failure risk equation (KFRE) to guide the referral of individuals with chronic kidney disease (CKD) to secondary kidney care services. People living...

Impact of Frailty on Performance of the Kidney Failure Risk Equation Using Creatinine- and Cystatin C-Based eGFR

Impact of Frailty on Performance of the Kidney Failure Risk Equation Using Creatinine- and Cystatin C-Based eGFR

A Feasibility Study Investigating the Role of Kidney Failure Risk Equation in Optimizing the Timing of Vascular Access Creation

A Feasibility Study Investigating the Role of Kidney Failure Risk Equation in Optimizing the Timing of Vascular Access Creation

Correlating Kidney Failure Risk Equation and Kidney Biopsy Chronicity Score as Kidney Failure Predicting Tools

Correlating Kidney Failure Risk Equation and Kidney Biopsy Chronicity Score as Kidney Failure Predicting Tools

Does Clinical Utility of the Kidney Failure Risk Equation in Routine Clinical Practice Vary by Socioeconomic Status?

Does Clinical Utility of the Kidney Failure Risk Equation in Routine Clinical Practice Vary by Socioeconomic Status?

Investigation of end-stage kidney disease risk prediction in an ethnically diverse cohort of people with type 2 diabetes: use of kidney failure risk equation

IntroductionThe four variable kidney failure (KF) risk equation (KFRE) is recommended to estimate KF risk (ie, need for dialysis or kidney transplantation). Earlier referral to clinical kidney services for people...

Estimates of eskd risk and timely kidney replacement therapy education

BackgroundKidney replacement therapy (KRT) needs preparation and its timing is difficult to predict. Nephrologists’ predictions of kidney failure risk tend to be more pessimistic than the Kidney Failure Risk Equation (KFRE) predictions. We aimed to explore how physicians’ risk estimate related to referral to KRT education, vs. the objective calculated KFRE.MethodsProspective observational study of data collected in chronic kidney disease (CKD) clinics of the Veterans Affairs Medical Center San Diego and the University of California, San Diego. The study included 257 participants who were aged 18 years or older, English speaking, prevalent CKD clinic patients, with estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m2 (MDRD equation). The exposure consisted of end stage kidney disease (ESKD) risk predictions. Nephrologists’ kidney failure risk estimations were assessed: “On a scale of 0–100%, without using any estimating equations, give your best estimate of the risk that this patient will need dialysis or a kidney transplant in 2 years.” KFRE was calculated using age, sex, eGFR, serum bicarbonate, albumin, calcium, phosphorus, urine albumin/creatinine ratio. The outcomes were the pattern of referral to KRT education (within 90 days of initial visit) and kidney failure evaluated by chart review. The population was divided into groups either by nephrologists’ predictions or by KFRE. Referral to KRT education was examined by group and sensitivity and specificity were calculated based on whether participants reached kidney failure at 2 years.ResultsA fifth were referred for education by 90 days of enrollment. Low risk patients by both estimates had low referral rates. In those with nephrologists’ predictions ≥ 15% (n = 137), sensitivity was 71% and specificity 76%. In those with KFRE ≥ 15% (n = 55), sensitivity was 85% and specificity 41%.ConclusionsAlthough nephrologists tend to overestimate patients’ kidney failure risk, they do not appear to act on this overestimation, as the rates of KRT education referrals are lower than expected when a nephrologist identifies a patient as high risk.Clinical Trial NumberNot applicable

Validation of histopathological chronicity scores in native kidney biopsies using light microscopy and digital morphometry for predicting renal outcome

Quantitative assessment of chronicity changes in native kidney biopsies offer valuable insights in to disease prognosis, despite the strength of qualitative information. Yet, standardization and reproducibility remain challenging. The present study aims to assess and compare the prognostic utility and reproducibility of two chronicity scoring systems based on light microscopy and whole slide imaging with morphometry and also to evaluate the prognostic utility of structural measurements: cortical non-sclerotic glomerular (NSG) density and NSG area/volume. We designed a retrospective longitudinal study involving 101 adult and paediatric patients who underwent native kidney biopsies. Chronicity scoring was performed using two semi-quantitative methods: Method 1 (method proposed in PMID: 28314581) and Method 2 (method proposed in PMID: 32516862), under light microscopy as well as on whole-slide scanned images, and assessed for prognostic utility. Kidney-Failure-Risk-Equation (KFRE) was employed in combination with chronicity-scoring-methods and assessed for predictive capability. Interobserver reproducibility for the two chronicity methods was studied among three renal pathologists. Structural measurements were performed on whole-slide- scanned-images. Both the chronicity scoring methods significantly predicted decline in estimated glomerular filtration rate (eGFR) and persistent need for renal replacement therapy in follow-up. Method 1 combined with KFRE, outperformed Method 2 in predicting renal survival. Method 2 however showed higher interobserver reproducibility. Combined KFRE plus histopathological scoring methods showed better predictive accuracy. The study validates the precision of chronicity scoring using whole slide scanned images. The morphometric structural measurements showed significant correlations with follow-up eGFR, thereby providing supplementary prognostic information.

Enhancing vascular access planning in CKD: validating the 40% KFRE threshold for predicting ESKD in a French retrospective cohort study.

Establishing the optimal timing for creating vascular access in patients with chronic kidney disease (CKD) is a critical and challenging aspect of patient management. The Kidney Disease: Improving Global Outcomes guidelines propose using a 40% 2-year threshold based on the Kidney Failure Risk Equation (KFRE) for this purpose. However, the effectiveness of this threshold compared with traditional methods, such as estimated glomerular filtration rate (eGFR), is not well-established. In this monocentric retrospective cohort study, we analyzed data from patients referred for vascular mapping before arteriovenous fistula (AVF) creation between April 2013 and June 2023. The study aimed to compare the ≥40% 2-year KFRE threshold with a <15mL/min/1.73 m² eGFR threshold for predicting end-stage kidney disease (ESKD). We assessed the probability of ESKD, considering death before AVF creation as a competing risk. Discrimination between KFRE and eGFR was evaluated using C-statistics. The study included 238 patients with a mean age of 65.2years and a mean eGFR of 13.3mL/min/1.73 m². Over a median follow-up of 10.7months, 178 patients developed ESKD, and 21 died before ESKD. Probability of ESKD at 1year was 77.6% (95% CI 69.9%-85.3%) using a ≥40% 4-variable KFRE threshold versus 65.8% (95% CI 58.3%-73.3%) using a <15mL/min/1.73 m² eGFR threshold. The C-statistics indicated better predictive ability for the 8-variable KFRE at 6months [0.82 (95% CI 0.76-0.88)], while both 4- and 8-variable KFRE models were effective for 1-year predictions [0.835 (95% CI 0.78-0.89) and 0.82 (95% CI 0.76-0.875), respectively]. Sensitivity and specificity analyses favored the ≥40% KFRE threshold over the eGFR threshold. This study suggests that using a ≥40% 2-year KFRE threshold for planning vascular access in CKD patients is promising and potentially superior to the traditional <15mL/min/1.73 m² eGFR threshold. This approach may offer a balance between minimizing premature AVF creation and the risk of starting dialysis via a central venous catheter.

TrajVis: a visual clinical decision support system to translate artificial intelligence trajectory models in the precision management of chronic kidney disease.

Our objective is to develop and validate TrajVis, an interactive tool that assists clinicians in using artificial intelligence (AI) models to leverage patients' longitudinal electronic medical records (EMRs) for personalized precision management of chronic disease progression. We first perform requirement analysis with clinicians and data scientists to determine the visual analytics tasks of the TrajVis system as well as its design and functionalities. A graph AI model for chronic kidney disease (CKD) trajectory inference named DisEase PrOgression Trajectory (DEPOT) is used for system development and demonstration. TrajVis is implemented as a full-stack web application with synthetic EMR data derived from the Atrium Health Wake Forest Baptist Translational Data Warehouse and the Indiana Network for Patient Care research database. A case study with a nephrologist and a user experience survey of clinicians and data scientists are conducted to evaluate the TrajVis system. The TrajVis clinical information system is composed of 4 panels: the Patient View for demographic and clinical information, the Trajectory View to visualize the DEPOT-derived CKD trajectories in latent space, the Clinical Indicator View to elucidate longitudinal patterns of clinical features and interpret DEPOT predictions, and the Analysis View to demonstrate personal CKD progression trajectories. System evaluations suggest that TrajVis supports clinicians in summarizing clinical data, identifying individualized risk predictors, and visualizing patient disease progression trajectories, overcoming the barriers of AI implementation in healthcare. The TrajVis system provides a novel visualization solution which is complimentary to other risk estimators such as the Kidney Failure Risk Equations. TrajVis bridges the gap between the fast-growing AI/ML modeling and the clinical use of such models for personalized and precision management of chronic diseases.

Minimisation of dialysis risk in hospital patients with chronic kidney disease (MinDial): study protocol for a multicentre, stepped-wedge, cluster-randomised controlled trial

BackgroundEarly identification of patients with chronic kidney disease (CKD) and advancing kidney insufficiency, followed by specialist care, can decelerate the progression of the disease. However, awareness of the importance and possible consequences of kidney insufficiency is low among doctors and patients. Since kidney insufficiency can be asymptomatic even in higher stages, it is often not even known to those belonging to risk groups. This study aims to clarify whether, for hospitalised patients with advanced chronic kidney disease, a risk-based appointment with a nephrology specialist reduces disease progression.MethodsThe target population of the study is hospitalised CKD patients with an increased risk of end-stage renal disease (ESRD), more specifically with an ESRD risk of at least 9% in the next 5 years. This risk is estimated by the internationally validated Kidney Failure Risk Equation (KFRE). The intervention consists of a specific appointment with a nephrology specialist after the hospital stay, while control patients are discharged from the hospital as usual. Eight medical centres include participants according to a stepped-wedge design, with randomised sequential centre-wise crossover from recruiting patients into the control group to recruitment to the intervention. The estimated glomerular filtration rate (eGFR) is measured for each patient during the hospital stay and after 12 months within the regular care by the general practitioner. The difference in the change of the eGFR over this period is compared between the intervention and control groups and considered the primary endpoint.DiscussionThis study is designed to evaluate the effect of risk-based appointments with nephrology specialists for hospitalised CKD patients with an increased risk of end-stage renal disease. If the intervention is proven to be beneficial, it may be implemented in routine care. Limitations will be examined and discussed. The evaluation will include further endpoints such as non-guideline-compliant medication, economic considerations and interviews with contributing physicians to assess the acceptance and feasibility of the intervention.Trial registrationGerman Clinical Trials Register DRKS00029691. Registered on 12 September 2022.

#2958 Can the Kidney Failure Risk Equation (KFRE) be used in ANCA associated glomerulonephritis?

Abstract Background and Aims The Kidney Failure Risk Equation (KFRE) provides a 2 and 5 year probability of treated kidney failure for a patient with chronic kidney disease (CKD) stage 3a to 5. KFRE has been validated in over 30 countries, including the United Kingdom (UK) and has become a useful tool to aid clinical decision making [1]. However there has been limited validation to determine if KFRE can be used in primary renal pathologies such as ANCA associated glomerulonephritis (AAGN). We conducted a retrospective cohort study of patients with AAGN at a single centre in Lancashire, UK to determine if KFRE accurately predicts end stage kidney disease (ESKD). Method Patients diagnosed with AAGN between 2009 and 2018 were screened for inclusion. Exclusion criteria included mortality within 6 months of diagnosis, those that remained dialysis dependent 6 months after diagnosis, transfer out of area, eGFR &amp;gt;60 ml/min/1.73 m2 and missing biochemical results required to calculate KFRE. Baseline and clinical characteristics were collected. The UK 4-variable KFRE was calculated at 6 months (±3 months) and 18 months (±3 months) after initial diagnosis of AAGN (1). Clinical outcomes including ESKD (dialysis or transplantation) were recorded. Statistical analysis was performed. The median and interquartile range were used for continuous variables and frequency and percentage for absolute values. The median and interquartile range were calculated for KFRE. The area under the received operator characteristic curve (AUC) was used to calculate discrimination of KFRE. Results Of the 150 patients screened, 78 patients were included in this retrospective analysis. Median age at diagnosis was 67 years (IQR 61-74 years). Forty one (53%) males and 37 (47%) females were included in the study. Forty two (53.8%) patients had positive anti-MPO antibodies, 29 (37.2%) had anti-PR3 antibodies and 7 (9.0%) had seronegative AAGN. 15 of 78 patients required dialysis or transplantation within the study period assessed. KFRE was calculated at 6 months (± 3 months) ; the median 2 year risk KFRE score was 2% (IQR 0.3-5%) and median 5 year KFRE score was 7.1% (IQR 1.1-17.6%) (Fig. 1). KFRE was calculated at 18 months (± 3 months) ; the median 2 year risk KFRE score was 0.7% (IQR 0.4–2.7%) and median 5 year KFRE score was 2.1% (IQR 0.7–9.5%). In terms of discrimination for KFRE calculated 6 months after diagnosis, in the 2 year analysis, the AUC was 0.74 (95% CI 0.55-0.92) and in the 5 year analysis, the AUC was 0.73 (95% CI 0.55-0.90). When KFRE was calculated 18 months after diagnosis, in the 2 year analysis, the AUC was 0.75 (95% CI 0.30-1) and in the 5 year analysis, the AUC was 0.81 (95% CI 0.50-1). Conclusion While KFRE is a thoroughly validated and widely adopted tool in CKD patients, its application in primary renal pathologies, such as AAGN, is yet to be determined. We have shown that KFRE provides fair discrimination, as early as 6 months after initial diagnosis and may provide future clinical utility in AAGN patients that have achieved stable remission. Current tools to risk stratify AAGN patients require histological parameters which is not always possible to achieve and further work in predicting the prognosis of glomerular diseases is needed. This study was limited by the single centre and small cohort but further analysis and validation on a larger multi-centre cohort is needed before KFRE can be considered for clinical use in AAGN patients.

#1465 Enhancing vascular access planning in CKD: validating the 40% KFRE threshold in a French retrospective cohort study

Abstract Background and Aims The optimal timing for dialysis vascular access creation remains a complex clinical decision, balancing the risk of early intervention against the prospect of starting dialysis with a central venous catheter. This study sought to compare the predictive capabilities of the Kidney Failure Risk Equation (KFRE) and estimated Glomerular Filtration Rate (eGFR) in determining the appropriate timing for arteriovenous fistula (AVF) creation in patients with advanced chronic kidney disease (CKD). Method A retrospective cohort of 238 patients referred for ultrasound vascular mapping from April 2013 to June 2023 was analyzed. Data on patient characteristics, laboratory results, and clinical outcomes were collected. The 4-variable and 8-variable KFRE and eGFR were assessed for their ability to predict end-stage kidney disease (ESKD) within a 2-year period. Discrimination was evaluated using receiver operating characteristic (ROC) curves, and calibration was assessed graphically. Net benefit decision curves were utilized to compare the net benefit of the KFRE models at various threshold probabilities. Results The cohort comprised 238 patients with an average age of 65.2 years and a mean eGFR of 13.3 mL/min/m²73. During the median 10.7-month follow-up, 178 patients (74.8%) progressed to ESKD, and 21 (9.2%) died prior to reaching ESKD. At the 1-year mark, the probability of progressing to ESKD was 77.6% (95% CI, 69.9-85.3%) when a 40% threshold for the 4-variable KFRE was applied, compared to 65.8% (95% CI, 58.3-73.3%) with an eGFR threshold of 15 mL/min/m²73. Discrimination analysis demonstrated a superior predictive performance for the 8-variable KFRE at 6 months, with a C-statistic of 0.82 (95% CI: 0.76-0.88). At 1 year, both KFRE models showed strong predictive abilities, with C-statistics of 0.835 (95% CI: 0.78-0.89) for the 4-variable KFRE and 0.82 (95% CI: 0.76-0.875) for the 8-variable KFRE. Sensitivity and specificity analyses underscored the benefits of utilizing the 40% KFRE threshold for predicting ESKD over the eGFR threshold. Conclusion The study demonstrates that both the 4-variable and 8-variable KFRE are valuable tools for predicting the need for vascular access in pre-dialysis patients, outperforming eGFR alone. The 8-variable KFRE, in particular, provides a significant improvement in 6-months ESKD prediction, with potential implications for clinical decision-making and patient management in advanced CKD. These findings advocate for the incorporation of KFRE in the clinical evaluation process for timely and appropriate vascular access planning.

#559 Validation of the Kidney Failure Risk Equation (KFRE) in individuals with chronic kidney disease and multimorbidity

Abstract Background and Aims Increasing numbers of individuals with chronic kidney disease (CKD) experience multiple long-term conditions (multimorbidity). Clinical guidance recommends the use of validated risk prediction equations, such as the kidney failure risk equation (KFRE), to guide referral to specialist kidney care services. However, multimorbidity may impact the accuracy of creatinine-based eGFR and bias the prognostic utility of KFRE. Equations with alternative filtration markers, such as Cystatin C eGFR (eGFRcys) or the combined creatinine and Cystatin C eGFR (eGFRcrcys), may improve KFRE's risk stratification and discrimination of future kidney failure risks. This study aimed to validate the four-variable KFRE in individuals with CKD, with and without multimorbidity in a research-based cohort (UK Biobank) and a population-based cohort (Stockholm Creatinine Measurements project (SCREAM)). The study also assessed the performance of KFRE when using eGFRcr, eGFRcys and eGFRcrcys. Method Individuals from both cohorts were included if they had CKD, defined as eGFR&amp;lt;60 mL/min/1.73 m2 by any of the three eGFR equations (eGFRcr, eGFRcys and eGFRcrcys), and had available proteinuria measurement at time of testing or within the previous 12 months. Multimorbidity was defined as the presence of two or more long-term conditions in addition to CKD and was grouped into multimorbidity clusters based on previous research. The outcome was kidney failure, defined as the need for long-term dialysis or kidney transplantation. KFRE performance at 2- and 5-years was assessed using the area under the receiver operating characteristic curve and c-index for discrimination and calibration curves for calibration. Results We included 24 489 individuals from UK Biobank and 42 902 individuals from SCREAM (mean age 62.8 (SD 5.6) and 70.1 (SD14.1), 54% and 66% female, respectively). In UK biobank, 14 998 individuals had multimorbidity, of which 5 375 had cardiometabolic multimorbidity. In SCREAM, 30 147 had multimorbidity and 17 854 cardiometabolic multimorbidity. Overall, there were 252 and 312 kidney failure events and 1 108 and 1 471 death events in UK Biobank and 918 and 1 098 kidney failure events and 8 785 and 10 152 death events in SCREAM within 2- and 5-years respectively. Model performance was consistent across both cohorts. Discrimination power of KFRE was good in individuals with and without multimorbidity and across the 2-year and 5-year models (Table 1). Calibration plots revealed over-estimation of risk at 2-years in both cohorts and under-estimation of risk at 5-years in patients with multimorbidity in UK Biobank. There was no improvement in model performance when using eGFRcys or eGFRcrcys compared to eGFRCr. There was a higher cumulative incidence of both kidney failure and death in the multimorbidity group, with a prominent increase in risk of death over time compared to the no multimorbidity group. This was most evident in the SCREAM cohort (Fig. 1). Conclusion KFRE adequately predicts kidney failure in individuals with multimorbidity and either creatinine or cystatin C can be used. Given the high rates of mortality amongst people with multimorbidity, exploration of models that account for the competing risk of death is warranted.

#2840 Early tolerance of SGLT2i therapy in patients with ATTR V30M amyloidosis: staging the disease to establish standard of care

Abstract Background and Aims Studies of sodium-glucose co-transporter 2 inhibitors (SGLT2i) therapy on ATTR cardiomyopathy are scarce and focus wild-type and V122I. In ATTRv, namely V30M, SGLT2i introduction to preserve kidney function or improve cardiorenal syndrome is not an outlined practice. Our aim was to assess the clinical evolution and difficulties with SGLT2i therapy in ATTR V30M amyloidosis, a population with neurogenic bladder, dysautonomia and prone to dehydration. Methods Patients with ATTR V30M amyloidosis and criteria for SGLT2i started standard dosages. Gillmore score (GS) for ATTR cardiomyopathy, kidney failure risk equation (KFRE) and the renal system score (RSS) of the FASTEX model (Fabry disease) were calculated. Estimation of heart amyloid load was based on Tc-99-DPD scintigraphy. Results Eight patients were followed on median of 7 months [IQR 5.6-9.4]; 7 treated with dapagliflozin, 1 with empagliflozin. 6 had type-2 diabetes. 4 were treated with tafamidis, 1 inotersen and 1 patisiran. 3/7 had positive DPD scintigraphy. Heart failure decompensation, new arrhythmias and renal adverse events were absent. Neurogenic bladder was present in 4 patients, 2 had urinary tract infections. 1 had symptomatic hypotension, leading to discontinuation of therapy. EGFR and RSS improved in 5 and 3 patients, respectively; NT-proBNP/albuminuria/proteinuria and KFRE at 2 and 5 years decreased. In terms of cardiomyopathy, 1 patient improved to GSI; 2 using CKD-EPI creatinine and none using CKD-EPI cystatin C. 1 progressed to GSII in all equations. Conclusion In this pilot study, we evidenced that ATTR V30M patients meet the criteria for SGLT2i therapy. Dysautonomia and neurogenic bladder were not an impediment for therapy. In addition to disease modifying drugs, SGLT2i may improve kidney and cardiovascular outcomes in ATTR V30M amyloidosis.